#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4700	16S	1529	1529	100.0	16S.l15.c30.ctg.1	1947	430.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1315	1315	C	559	C,A	334,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8928	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3393	459.7	0	.	n	.	0	T695C	SNP	695	695	T	897	897	C	613	C,A	369,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8928	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3393	459.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1539	1539	A	450	A	286	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8928	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3393	459.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2173	2173	C	394	C	252	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8928	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3393	459.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2247	2247	A	436	A	270	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8928	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3393	459.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2799	2799	C	565	C	339	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	358	folP	852	852	100.0	folP.l15.c4.ctg.1	1556	42.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1081	1083	AGC	57;57;56	A;G;C	35;34;33	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	980	gyrA	2751	2222	99.82	gyrA.l15.c4.ctg.1	2426	57.1	1	SNP	p	S91F	0	.	.	271	273	TCC	475	477	TCC	62;63;63	T;C;C	36;39;39	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	980	gyrA	2751	2222	99.82	gyrA.l15.c4.ctg.1	2426	57.1	1	SNP	p	D95G	0	.	.	283	285	GAC	487	489	GAC	73;75;75	G;A;C	45;43;45	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	980	gyrA	2751	2222	99.82	gyrA.l15.c4.ctg.1	2426	57.1	1	SNP	p	D95N	0	.	.	283	285	GAC	487	489	GAC	73;75;75	G;A;C	45;43;45	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	980	gyrA	2751	425	100.0	gyrA.l15.c4.ctg.2	609	55.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	334	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1108	54.5	0	.	p	.	0	A40P	NONSYN	118	120	GCC	342	344	CCC	65;65;65	C;C;C	39;39;41	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	334	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1108	54.5	1	SNP	p	G45D	0	.	.	133	135	GGC	357	359	GGC	57;57;57	G;G,A;C,A	37;35,1;37,1	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	860	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2790	54.5	1	SNP	p	D86N	0	.	.	256	258	GAC	421	423	GAC	66;66;66	G;A;C	40;32;36	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	860	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2790	54.5	1	SNP	p	S87I	0	.	.	259	261	AGT	424	426	AGT	64;67;69	A;G;T,G	33;37;37,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	860	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2790	54.5	1	SNP	p	S87W	0	.	.	259	261	AGT	424	426	AGT	64;67;69	A;G;T,G	33;37;37,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	860	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2790	54.5	1	SNP	p	S87R	0	.	.	259	261	AGT	424	426	AGT	64;67;69	A;G;T,G	33;37;37,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	860	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2790	54.5	1	SNP	p	S88P	0	.	.	262	264	TCC	427	429	TCC	69;69;69	T;C;C	35;37;41	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	776	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2354	56.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1395	1397	GGC	48;48;48	G,T;G;C	33,1;31;29	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1119	1121	GCA	121;123;122	G;C;A	80;81;81	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1122	1124	ATC	128;128;128	A;T;C	83;83;84	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1134	1136	GTG	123;123;123	G;T;G	78;74;78	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1134	1136	GTG	123;123;123	G;T;G	78;74;78	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1638	1640	ACC	63;63;61	A;C;C	36;44;43	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1692	1694	GCG	36;35;36	G;C;G	26;25;24	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1692	1694	GCG	36;35;36	G;C;G	26;25;24	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1815	1817	GGC	51;51;51	G;G;C	33;32;30	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1824	1826	GGC	46;46;44	G;G;C	27;27;25	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2017	82.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1842	1844	CCG	31;28;28	C;C;G	17;15;16	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	V160S	NONSYN	478	480	GTA	148	150	TCA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	V444F	NONSYN	1330	1332	GTT	289	291	TTT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	P447R	NONSYN	1339	1341	CCG	298	300	CGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	S449G	NONSYN	1345	1347	AGC	304	306	GGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	F450L	NONSYN	1348	1350	TTT	307	309	TTG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	E451G	NONSYN	1351	1353	GAG	310	312	GGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	Q453R	NONSYN	1357	1359	CAG	316	318	CGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	A454G	NONSYN	1360	1362	GCG	319	321	GGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	0	.	p	.	0	T467S	NONSYN	1399	1401	ACC	358	360	AGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	409	411	ACC	6;6;6	A;C;C	3;3;3	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	463	465	GCG	4;4;4	G;C;G	2;2;2	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	924	penA	1749	409	94.84	penA.l6.c4.ctg.2	495	1.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	463	465	GCG	4;4;4	G;C;G	2;2;2	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1502	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2942	85.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1426	1428	CTG	75;73;74	C;T;G	45;41;42	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	438	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1775	44.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	585	585	C	35	C	21	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	414	416	GGA	73;73;75	G;G;A	40;41;42	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	675	677	CTT	54;54;54	C;T;T	33;34;36	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	699	701	GGA	55;58;58	G;G;A	34;32;33	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	783	785	GGT	68;68;68	G;G;T	39;37;36	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	837	839	AGC	71;71;71	A;G;C	39;40;41	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	903	903	T	59	T,A	34,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	1	SNP	p	G120K	0	.	.	358	360	GGT	630	632	GGT	50;52;52	G;G;T	34;32;32	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	1	SNP	p	A121N	0	.	.	361	363	GCC	633	635	GCC	52;52;53	G;C;C	34;33;34	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	490	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1523	58.6	1	SNP	p	A121D	0	.	.	361	363	GCC	633	635	GCC	52;52;53	G;C;C	34;33;34	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2402	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4432	95.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1723	1725	AAT	104;105;105	A;A;T	67;66;67	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	262	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1333	40.1	1	SNP	p	V57M	1	.	.	169	171	ATG	846	848	ATG	99;94;97	A;T,G;G,T	60;54,1;60,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
